Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: A 10-Year population-based case-control study

Journal of Clinical Psychiatry

Volumn 76, Issue 9, 2015, Pages 1216-1223

  Wu, Chi Shin ^a   Chang, Chia Ming ^a   Tsai, Yu Ting ^a   Huang, Ya Wen ^a   Tsai, Hui Ju ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MOPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; GENDER; HIP FRACTURE; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; TAIWAN; CHEMICALLY INDUCED; HIP FRACTURES; MIDDLE AGED; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; TAIWAN;

EID: 84943554125     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09098     Document Type: Article

References (39)

1. Kaufman JD, Cummings SR. Osteoporosis and prevention of fractures: practical approaches for orthopaedic surgeons. Instr Course Lect. 2002;51:559-565.
2. Shyu YI, Chen MC, Liang J, et al. Changes in quality of life among elderly patients with hip fracture in Taiwan. Osteoporos Int. 2004;15(2):95-102.
3. Grisso JA, Kelsey JL, Strom BL, et al; The Northeast Hip Fracture Study Group. Risk factors for falls as a cause of hip fracture in women. N Engl J Med. 1991;324(19):1326-1331.
4. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281(16):1505-1511.
5. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8):1033-1046.
6. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: A metaanalysis. Osteoporos Int. 2005;16(11):1330-1338.
7. Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: A review of the literature. Acta Psychiatr Scand. 2007;116(5):317-333.
8. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-645.
9. McGrath J, Saha S, Chant D, et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67-76.
10. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104.
11. Hugenholtz GW, Heerdink ER, van Staa TP, et al. Risk of hip/femur fractures in patients using antipsychotics. Bone. 2005;37(6):864-870.
12. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry. 2007;68(6):929-934.
13. Pouwels S, van Staa TP, Egberts AC, et al. Antipsychotic use and the risk of hip/femur fracture: A population-based case-control study. Osteoporos Int. 2009;20(9):1499-1506.
14. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand suppl. 1994;382:11-15.
15. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39(1):1-14.
16. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 2):3-7.
17. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002;63(suppl 4):56-62.
18. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133-135.
19. Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111(1):11-20.
20. Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiatry. 2003;160(9):1618-1620.
21. Lehman D, Meyer JM. Decreased bone mineral density in male schizophrenia patients. Schizophr Res. 2005;76(1):131-133.
22. Jung DU, Kelly DL, Oh MK, et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31(4):406-410.
23. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190(2):129-134.
24. Chen CY, Liu CY, Su WC, et al. Factors associated with the diagnosis of neurodevelopmental disorders: A populationbased longitudinal study. Pediatrics. 2007;119(2):e435-e443.
25. Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: World Health Organization; 2009.
26. Richards JB, Papaioannou A, Adachi JD, et al; Canadian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194.
27. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135(5):825-837.
28. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60(suppl 10):5-14.
29. Roth BL, Lopez E, Beischel S, et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: A novel approach for CNS drug discovery. Pharmacol Ther. 2004;102(2):99-110.
30. Cummings SR, Nevitt MC, Browner WS, et al; Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. N Engl J Med. 1995;332(12):767-773.
31. Pouwels S, Bazelier MT, de Boer A, et al. Risk of fracture in patients with Parkinson's disease. Osteoporos Int. 2013;24(8):2283-2290.
32. Kolanowski A, Fick D, Waller JL, et al. Outcomes of antipsychotic drug use in communitydwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217-225.
33. Jalbert JJ, Eaton CB, Miller SC, et al. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11(2):120-127.
34. Sorensen HJ, Jensen SO, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: A population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872-878.
35. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316(7):363-369.
36. Oderda LH, Young JR, Asche CV, et al. Psychotropic-related hip fractures: metaanalysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother. 2012;46(7-8):917-928.
37. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
38. Pietschmann P, Rauner M, Sipos W, et al. Osteoporosis: An age-related and genderspecific disease-a mini-review. Gerontology. 2009;55(1):3-12.
39. Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry. 2005;162(1):162-167.